MX347753B - Formulaciones resistentes al abuso. - Google Patents

Formulaciones resistentes al abuso.

Info

Publication number
MX347753B
MX347753B MX2012009780A MX2012009780A MX347753B MX 347753 B MX347753 B MX 347753B MX 2012009780 A MX2012009780 A MX 2012009780A MX 2012009780 A MX2012009780 A MX 2012009780A MX 347753 B MX347753 B MX 347753B
Authority
MX
Mexico
Prior art keywords
dosage form
abuse
hydrocodone
resistant formulations
sustained
Prior art date
Application number
MX2012009780A
Other languages
English (en)
Other versions
MX2012009780A (es
Inventor
Hamed Ehab
Kraling Carrie
Original Assignee
Cima Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cima Labs Inc filed Critical Cima Labs Inc
Publication of MX2012009780A publication Critical patent/MX2012009780A/es
Publication of MX347753B publication Critical patent/MX347753B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente revelación es concerniente con una forma de dosificación oral de liberación sostenida apropiada para una administración de dos veces al día que comprende una matriz que contiene un modificador de viscosidad y gránulos recubiertos que contienen hidrocodona. La forma de dosificación puede tener un perfil de liberación de tal manera que 6 horas enseguida de la administración, menos de aproximadamente de 80% de la hidrocodona es liberado. Además, la forma de dosificación puede tener resistencia al alcohol y/o resistencia al aplastamiento.
MX2012009780A 2010-02-24 2011-02-23 Formulaciones resistentes al abuso. MX347753B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30758810P 2010-02-24 2010-02-24
PCT/US2011/025914 WO2011106416A2 (en) 2010-02-24 2011-02-23 Abuse-resistant formulations

Publications (2)

Publication Number Publication Date
MX2012009780A MX2012009780A (es) 2012-09-12
MX347753B true MX347753B (es) 2017-05-10

Family

ID=43896837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012009780A MX347753B (es) 2010-02-24 2011-02-23 Formulaciones resistentes al abuso.

Country Status (11)

Country Link
US (2) US20130209560A1 (es)
EP (1) EP2538928B1 (es)
JP (1) JP6141583B2 (es)
CN (1) CN102770127B (es)
AU (1) AU2011220813B2 (es)
CA (1) CA2790108C (es)
ES (1) ES2628886T3 (es)
IL (1) IL221409A (es)
MX (1) MX347753B (es)
NZ (1) NZ602075A (es)
WO (1) WO2011106416A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100889069B1 (ko) 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2738302A (en) 2000-10-30 2002-05-15 Euro Celtique Sa Controlled release hydrocodone formulations
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
US8597681B2 (en) 2009-12-22 2013-12-03 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
ME02874B (me) 2010-12-22 2018-04-20 Purdue Pharma Lp Obloženi dozni oblici sa kontrolisanim oslobađanjem otporni na zloupotrebu
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US9050335B1 (en) 2011-05-17 2015-06-09 Mallinckrodt Llc Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
ES2628303T3 (es) * 2011-06-01 2017-08-02 Fmc Corporation Formas de dosis sólidas de liberación controlada
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
CA2883077C (en) * 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
WO2016004170A1 (en) 2014-07-03 2016-01-07 Mallinckrodt Llc Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
WO2018013771A1 (en) * 2016-07-13 2018-01-18 Cima Labs Inc. Treatment of pain using hydrocodone formulations
WO2018119033A1 (en) * 2016-12-20 2018-06-28 Cima Labs Inc. Abuse-resistant and abuse-deterrent dosage forms
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
EP3856160A4 (en) 2018-09-25 2022-07-06 SpecGx LLC ABUSE-PROOF IMMEDIATE RELEASE CAPSULE DOSAGE FORMS
IT201800011125A1 (it) 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
IT202000011050A1 (it) 2020-05-14 2021-11-14 Mogon Pharmaceuticals Sagl Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di ingredienti attivi
IT202000011053A1 (it) 2020-05-14 2021-11-14 Int Health Science S R L Composizioni orali solide comprendenti matrici monolitiche composite per la somministrazione cronotropica nel tratto gastroenterico di alimenti, integratori alimentari, nutraceutici, dispositivi medici

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959219A (en) * 1988-08-15 1990-09-25 Fisons Corporation Coating barriers comprising ethyl cellulose
US5223264A (en) 1989-10-02 1993-06-29 Cima Labs, Inc. Pediatric effervescent dosage form
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
KR100889069B1 (ko) * 1999-10-29 2009-03-17 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
DE10025947A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination enthaltend Montirelin und eine Verbindung mit opioider Wirksamkeit
DE10025948A1 (de) * 2000-05-26 2001-11-29 Gruenenthal Gmbh Wirkstoffkombination
JP2005515960A (ja) * 2001-05-11 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 乱用耐性のオピオイド投薬形態
US6813297B2 (en) * 2002-07-16 2004-11-02 Agilent Technologies, Inc. Material systems for long wavelength lasers grown on GaSb or InAs substrates
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
FR2881652B1 (fr) * 2005-02-08 2007-05-25 Flamel Technologies Sa Forme pharmaceutique orale microparticulaire anti-mesuage
US20070141147A1 (en) * 2005-12-21 2007-06-21 Auriga Laboratories, Inc. Sequential release pharmaceutical formulations
FR2901478B1 (fr) * 2006-05-24 2015-06-05 Flamel Tech Sa Forme pharmaceutique orale multimicroparticulaire a liberation prolongee
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US8445018B2 (en) * 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
WO2009035474A1 (en) * 2007-09-13 2009-03-19 Cima Labs Inc. Abuse resistant drug formulation
US8486448B2 (en) * 2007-12-17 2013-07-16 Paladin Labs Inc. Misuse preventative, controlled release formulation

Also Published As

Publication number Publication date
US20180049974A1 (en) 2018-02-22
AU2011220813B2 (en) 2016-05-19
EP2538928B1 (en) 2017-05-03
CA2790108C (en) 2016-05-31
MX2012009780A (es) 2012-09-12
US20130209560A1 (en) 2013-08-15
CN102770127A (zh) 2012-11-07
CA2790108A1 (en) 2011-09-01
WO2011106416A2 (en) 2011-09-01
IL221409A (en) 2017-04-30
JP2013520514A (ja) 2013-06-06
CN102770127B (zh) 2015-04-15
AU2011220813A1 (en) 2012-09-27
NZ602075A (en) 2014-01-31
WO2011106416A3 (en) 2012-03-01
JP6141583B2 (ja) 2017-06-07
IL221409A0 (en) 2012-10-31
EP2538928A2 (en) 2013-01-02
ES2628886T3 (es) 2017-08-04

Similar Documents

Publication Publication Date Title
MX347753B (es) Formulaciones resistentes al abuso.
NZ600640A (en) Abuse-resistant formulations
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
MX2012013021A (es) Formulaciones resistentes a alcohol.
MX2013007057A (es) Metodos para producir composiciones farmaceuticas estabilizadas de dosis solida que contienen morfinanos.
EP3626253A3 (en) Stable formulations of linaclotide
MX336038B (es) Composiciones farmaceuticas de liberacion controlada de tapentadol.
WO2008135527A3 (en) Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
WO2011104652A3 (en) Veterinary compositions
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
TN2012000574A1 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
MY157673A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012052169A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten
PH12016500693A1 (en) Slow-release solid oral compositions
PH12015502093A1 (en) Antiemetic extended release solid dosage forms
MX2012013023A (es) Formas de dosificacion de liberacion prolongada resistentes ala alcohol y que comprenden venlafaxina.
HK1174276A (en) Abuse-resistant formulations
PH12013500727A1 (en) Sustained-release pharmaceutical composition
UA97076C2 (ru) Мазь противовоспалительная на основе сульфаниламида
HK1182013A (en) Alcohol-resistant formulations
MX2010009500A (es) Formas de dosificacion oral solidas de valsartan y metodos para hacer estas formulaciones.
UA98018C2 (ru) Лекарственное средство с модифицированным характером высвобождения действующего вещества
HK1182030A (en) Alcohol-resistant extended release dosage forms comprising venlafaxine

Legal Events

Date Code Title Description
FG Grant or registration